NCT02322658CompletedPhase 1
An Open Label, Balanced, Randomized, Two-Treatment, Two Period, Two-Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited, and 'LUNESTA' Tablets 3 mg, Mfg For Sepracor Inc. USA In Healthy Adult Human Subjects Under Fed Conditions.
Dr. Reddy's Laboratories Limited1 site in 1 country46 target enrollmentStarted: September 2008Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 46
- Locations
- 1
- Primary Endpoint
- Area under curve
Study Overview
Brief Summary
This is an open-label, randomized, two-period, two-treatment, two-sequence, balanced, single dose, crossover, oral bioequivalence study in healthy, adult, human subjects under fed conditions.
Detailed Description
An open label, balanced, randomized, two-treatment, two-period, two-sequence,single dose, crossover, oral bioequivalence study of Eszopiclone tablets 3 mg of Dr. Reddy's Laboratories limited, and 'LUNESTA' tablets 3 mg Mfg for Sepracor Inc. USA in healthy adult human subjects under fed conditions.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The subjects should be healthy human between 18 and 45 years.
- •The subjects should be screened within 21 days prior to the administration of first dose of the study drug.
- •The subjects should have a BMI between 18.5 and 24.9 weight in kg/ height2 in meter.
- •The subjects should be able to communicate effectively with study personnel.
- •The subjects should be able to give written informed consent to participate in the study.
- •If subject is a female volunteer and
- •Is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence or
- •Is postmenopausal for at least 1 year or
- •Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).
Exclusion Criteria
- •The subjects who have a history of allergic responses to Eszopiclone or other related drugs.
- •The subjects who have significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, ECG and X-ray recordings.
- •The subjects who have any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •The subjects who have a history or presence of bronchial asthma.
- •Use of enzyme-modification drugs within 30 days prior to receiving the first dose of study medication.
- •History of drug dependence, recent history of alcoholism or of moderate alcohol use.
- •The subjects who are smokers who smoke more than or equal to 10 cigarettes per day or more than or equal to 20 biddies per day or those who cannot refrain from smoking during study period.
- •The subjects with a history of difficulty with donating blood or difficulty in accessibility of veins.
- •The subjects who have donated (1 unit 350 ml / 450 ml) blood within 90 days prior to receiving the first dose of study medication.
- •The subjects who have a positive hepatitis screen (includes subtypes A, B, C & E).
- •The subjects who have a positive test result for HIV antibody and / or syphilis (RPR/VDRL).
- •The subject who receives an investigational product, or has participated in a drug research study within a period of 90 days prior to the first dose of the study medication administration.
- •Female volunteers demonstrating a positive pregnancy screen.
- •Female volunteers who are currently breast-feeding.
- •Female volunteers not willing to use contraception during the study.
Arms & Interventions
Eszopiclone Tablets
Experimental
Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
Intervention: Eszopiclone Tablets 3 mg (Drug)
Lunesta
Active Comparator
Lunesta Tablets 3 mg of Sepracor Inc.
Intervention: Eszopiclone Tablets 3 mg (Drug)
Outcomes
Primary Outcomes
Area under curve
Time Frame: 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 24.0, 36.0 and 48.0 hours post dose.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fasting ConditionsHealthyNCT02322645Dr. Reddy's Laboratories Limited46
Completed
Phase 1
Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting ConditionsHealthyNCT03706300Dr. Reddy's Laboratories Limited80
Completed
Phase 1
Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting ConditionFasting StateNCT01578252IPCA Laboratories Ltd.48
Completed
Phase 1
Bioequivalence Study of Risperidone Tablet 1 mg Under Fed ConditionFedNCT01618760IPCA Laboratories Ltd.48
Completed
Phase 1
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed ConditionsFedNCT01827878IPCA Laboratories Ltd.48